surpass 6 tirzepatide Tirzepatide is finally here – what's the big deal? – GP Voice

A) The SURPASS Program (SURPASS1–6). TZP, Tirzepatide; FSG, Fasting

27.54

★★★★☆4.8 (126)

Semaglutide. Tirzepatide. The names dominate headlines: “Game-changing weight loss injections.” “A revolution in diabetes care.” But beyond the buzz, here's what the evidence says: Glycemic control: Landmark trials ( SURPASS, SUSTAIN) show significant

22.87

★★★★★4.9 (98)

Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6)

28.59

★★★★★5.0 (157)

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

29.92

★★★★★4.7 (84)

Frias_Tirzepatide: Overview of SURPASS Trials in Patients With Type 2 Diabetes

23.87

★★★★★4.9 (203)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

26.19

★★★★★5.0 (176)

Diabetes Distilled: “Twincretin” tirzepatide significantly SURPASSes comparator effects on glucose, weight and quality of life

28.93

★★★★★4.8 (132)